Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Checkpoint inhibitor-induced bullous pemphigoid differs from spontaneous bullous pemphigoid.
Kramer N, Müller G, Zierold S, Röckel M, Fröhlich W, Schefzyk M, Kumbrink J, Hassel JC, Berking C, Ziemer M, Nashan D, French LE, Vera J, Kerl-French KE, Gutzmer R, Heinzerling L. Kramer N, et al. Among authors: berking c. J Eur Acad Dermatol Venereol. 2024 Feb 24. doi: 10.1111/jdv.19860. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38400651 No abstract available.
[No title available]
[No authors listed] [No authors listed] PMID: 38212929
Sonnenschutz bei Beschäftigten im Freien. Entwicklung und Validierung von standardisierten Fragebögen für Verhalten und Wissen: Sun protection in outdoor workers – Development and validation of standardized questionnaires for behavior and knowledge.
Rönsch H, Rocholl M, Ludewig M, Staudt A, Langner M, Steeb T, Wilke A, John SM, Berking C, Beissert S, Bauer A. Rönsch H, et al. Among authors: berking c. J Dtsch Dermatol Ges. 2024 May;22(5):665-674. doi: 10.1111/ddg.15378_g. J Dtsch Dermatol Ges. 2024. PMID: 38730530 German.
Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy.
Lischer C, Eberhardt M, Flamann C, Berges J, Güse E, Wessely A, Weich A, Retzlaff J, Dörrie J, Schaft N, Wiesinger M, März J, Schuler-Thurner B, Knorr H, Gupta S, Singh KP, Schuler G, Heppt MV, Koch EAT, van Kleef ND, Freen-van Heeren JJ, Turksma AW, Wolkenhauer O, Hohberger B, Berking C, Bruns H, Vera J. Lischer C, et al. Among authors: berking c. J Immunother Cancer. 2024 May 9;12(5):e008104. doi: 10.1136/jitc-2023-008104. J Immunother Cancer. 2024. PMID: 38724462 Free PMC article.
Patients' and dermatologists' preferences in artificial intelligence-driven skin cancer diagnostics: A prospective multicentric survey study.
Haggenmüller S, Maron RC, Hekler A, Krieghoff-Henning E, Utikal JS, Gaiser M, Müller V, Fabian S, Meier F, Hobelsberger S, Gellrich FF, Sergon M, Hauschild A, Weichenthal M, French LE, Heinzerling L, Schlager JG, Ghoreschi K, Schlaak M, Hilke FJ, Poch G, Korsing S, Berking C, Heppt MV, Erdmann M, Haferkamp S, Drexler K, Schadendorf D, Sondermann W, Goebeler M, Schilling B, Kather JN, Fröhling S, Kaminski K, Doppler A, Bucher T, Brinker TJ; Collaborators. Haggenmüller S, et al. Among authors: berking c. J Am Acad Dermatol. 2024 Apr 24:S0190-9622(24)00649-2. doi: 10.1016/j.jaad.2024.04.033. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38670313 Free article. No abstract available.
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L. Albrecht LJ, et al. Among authors: berking c. Eur J Cancer. 2024 May;202:113976. doi: 10.1016/j.ejca.2024.113976. Epub 2024 Mar 1. Eur J Cancer. 2024. PMID: 38484692 Free article.
404 results